(Diphtheria + pertussis (acellular) + tetanus) vaccine is under clinical development by Serum Institute of India and currently in Phase I for Pertussis (Whooping Cough). According to GlobalData, Phase I drugs for Pertussis (Whooping Cough) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Diphtheria + pertussis (acellular) + tetanus) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Diphtheria + pertussis (acellular) + tetanus) vaccine overview

Vaccine candidate is under development for the prevention of diphtheria, tetanus and acellular pertussis. The therapeutic candidate consists of CpG 1018 adjuvant. It is administered through intramuscular route. The vaccine contains a component of Vaxiclase technology.

Serum Institute of India overview

Serum Institute of India (Serum Institute), a subsidiary of Cyrus Poonawalla Group, is a biotechnology company that manufactures and supplies vaccines and immuno-biologicals to treat polio, diphtheria, tetanus, pertussis, r-hepatitis B, measles, mumps and rubella. The company’s product portfolio includes bacterial, viral, covid, influenza, polysaccharide conjugate and combination vaccines; recombinant and pharma products; and anti-sera vaccines. It markets the Oxford–AstraZeneca COVID-19 vaccine under the brand name Covishield in India. It is investigating DTaP, an acellular vaccine against pertussis; pentavalent meningococcal conjugate vaccine to prevent epidemic group A meningococcal disease; ErepoXen, to maintain red blood cell production and prevent anemia caused by chronic kidney failure; and HPV vaccine against cervical cancer. Serum Institute is headquartered in Pune, Maharashtra, India

For a complete picture of (Diphtheria + pertussis (acellular) + tetanus) vaccine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.